US Apheresis Market

In 2024, Therapeutic Apheresis dominated the market share, driven by its critical role in treating autoimmune and neurological disorders, as well as its increasing adoption in hospitals and specialty clinics. This segment's growth is further supported by rising prevalence of chronic diseases and advancements in apheresis technology.

However, the fastest-growing segment over the forecast period (2025–2035) is expected to be Stem Cell Collection and Processing. This growth is attributed to increasing applications in regenerative medicine, rising demand for stem cell transplantation, and ongoing research in cell-based therapies.

The segment is also benefitting from expanding clinical trials and growing awareness about stem cell banking. These trends highlight a dynamic shift in the market, with innovation and personalized medicine driving future demand.

In 2024, the Hematologic Disorders segment held the largest market share due to the high prevalence of blood-related conditions such as leukemia, lymphoma, and sickle cell disease that require apheresis as part of their treatment. The demand is also driven by increasing awareness and advancements in transfusion medicine.

However, the Oncology segment is projected to be the fastest-growing during the 2025–2035 forecast period. This growth is fueled by the rising incidence of cancer, growing use of apheresis in cell therapy and immunotherapy, and expanding clinical research in oncology-focused treatments.

The market dynamics reflect a growing reliance on apheresis as a supportive and therapeutic tool in both chronic and life-threatening disease management.

In 2024, the Blood Banks segment accounted for the largest market share due to the high demand for blood component separation, donor apheresis procedures, and the growing need for safe and efficient blood supply management. Blood banks play a critical role in meeting the needs of patients requiring plasma, platelets, and other blood components.

However, the Research Laboratories segment is projected to witness the fastest growth during the forecast period (2025–2035). This is driven by increased investments in biomedical research, advancements in cell therapy and gene therapy, and the growing use of apheresis in experimental treatments and clinical trials.

The expanding focus on personalized medicine and innovation in therapeutic approaches is expected to accelerate demand for apheresis services within research environments.

The market in the South is projected to reach USD 757.67 million by 2035, growing at the highest compound annual growth rate (CAGR) of 9.63% during the forecast period. This growth is driven by a high concentration of healthcare facilities, rising prevalence of chronic diseases.

It is also driven by increasing adoption of advanced apheresis technologies, and supportive state-level healthcare initiatives. Additionally, the presence of major blood banks and research institutions further boosts demand for apheresis services in the region.

The South’s growing population and expanding access to specialized treatments also contribute to its leading position and rapid market expansion within the U.S. apheresis services landscape.